(Q37970443)

26 August 2017

title

Update on the role of rituximab in kidney diseases and transplant (English)

1 reference

26 August 2017

1 reference

1 reference

Vinayak Ramanath

1

1 reference

26 August 2017

Ravi Nistala

series ordinal

2

1 reference

26 August 2017

Kunal Chaudhary

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

21 December 2011

1 reference

Expert Opinion on Biological Therapy

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

223-233

1 reference

Drug insight: rituximab in renal disease and transplantation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

The role of B cells in lpr/lpr-induced autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

B cells as antigen presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab: beyond simple B cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Use of monoclonal antibodies in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab therapy in lupus nephritis: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Interventions for renal vasculitis in adults. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab as a therapeutic tool in severe mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab therapy for membranous nephropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab treatment of idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab in refractory nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab and intravenous immune globulin for desensitization during renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

B-cell-depleting induction therapy and acute cellular rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Targeting B cells and antibody in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Rituximab for the treatment of type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.646984

10.1517/14712598.2012.646984

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference